Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 3:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Scar Prevention Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Light Emitting Diode-Red Light (LED-RL) Phototherapy for Skin Scarring Prevention

NCT03795116
View directory record Official record
Conditions
Fibrosis, Skin Scarring, Skin Wound, Hypertrophic Scar, Scar, Keloid
Interventions
LED-RL phototherapy, Mock irradiation
Device
Lead sponsor
State University of New York - Downstate Medical Center
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Oct 28, 2026, 3:53 PM EDT
Terminated Not applicable Interventional

Scar Prevention Using Fractional Carbon Dioxide Laser Treatment

NCT01826942
View directory record Official record
Conditions
Scar Prevention
Interventions
Lumenis UltraPulse single fractional CO2 laser treatment thin skin, Single fractional CO2 treatment at surgical area closure procedure on thick skin
Device
Lead sponsor
Lumenis Be Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2014 · Synced Oct 28, 2026, 3:53 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty

NCT01037985
View directory record Official record
Conditions
Scar Prevention
Interventions
EXC 001, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 45 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
6
States / cities
La Jolla, California • Chicago, Illinois • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 28, 2026, 3:53 PM EDT
Completed No phase listed Observational

The Relationship of Rehabilitation Therapy Time To The Prevention of Burn Scar Contracture

NCT01161810
View directory record Official record
Conditions
Burns
Interventions
Routine post burn rehabilitation therapy
Other
Lead sponsor
American Burn Association
Other
Eligibility
18 Years to 90 Years
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
14
States / cities
Phoenix, Arizona • Orange, California • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2023 · Synced Oct 28, 2026, 3:53 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Randomized Controlled Trial Examining the Efficacy of Botulinum Toxin in Biopsy Scar Minimization

NCT05478551
View directory record Official record
Conditions
Scar, Hypertrophic Scar
Interventions
Botulinum Toxin, Normal saline
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 28, 2026, 3:53 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy Study of Different Dose Levels of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty

NCT01038297
View directory record Official record
Conditions
Scar Prevention
Interventions
EXC 001, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Chicago, Illinois • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Oct 28, 2026, 3:53 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Additional Doses of AZX100 Drug Product Following Excision of Keloid Scars

NCT00892723
View directory record Official record
Conditions
Scar Prevention, Scar Reduction
Interventions
AZX100 Drug Product, Placebo
Drug
Lead sponsor
Capstone Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Pasadena, California • Philadelphia, Pennsylvania • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Oct 28, 2026, 3:53 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Pilot Study of Apligraf for the Treatment and Prevention of Recurrence of Excised Keloids

NCT00587587
View directory record Official record
Conditions
Keloid
Interventions
Apligraf, Standard dressing regimen
Device · Other
Lead sponsor
Organogenesis
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Miami Beach, Florida
Source: ClinicalTrials.gov public record
Updated Aug 19, 2011 · Synced Oct 28, 2026, 3:53 PM EDT
Recruiting Phase 2 Interventional

Cleft Lip Scarring After Botox

NCT07880860
View directory record Official record
Conditions
Cleft Lip, Cleft Lip Scar
Interventions
Botulinum Toxin Type A (BOTOX) Injection, Normal Saline
Drug
Lead sponsor
Children's National Research Institute
Other
Eligibility
0 Days to 12 Months
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 28, 2026, 3:53 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Hypertrophic Scar Prevention by Novel Topical Gel Application

NCT03403621
View directory record Official record
Conditions
Hypertrophic Scar
Interventions
Pentamidine Isethionate, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 28, 2026, 3:53 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Evaluation of the Efficacy, Tolerability, and Patient Acceptance of Dermatix Q for the Prevention and Management of Scars

NCT00450775
View directory record Official record
Conditions
Scars
Interventions
Dermatix Q
Drug
Lead sponsor
Innovative Medical
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Sep 25, 2008 · Synced Oct 28, 2026, 3:53 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults

NCT02079168
View directory record Official record
Conditions
Keloid
Interventions
RXI-109, Placebo
Drug
Lead sponsor
RXi Pharmaceuticals, Corp.
Industry
Eligibility
21 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Miami, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 14, 2016 · Synced Oct 28, 2026, 3:53 PM EDT
Suspended Phase 3 Interventional

Evaluation of Adhexil Safety and Efficacy in Prevention and/or Reduction of Adhesions in Gynecological Surgery

NCT00865488
View directory record Official record
Conditions
Ovarian Cysts, Endometriosis, Adhesions
Interventions
ADHEXIL
Biological
Lead sponsor
OMRIX Biopharmaceuticals
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 23, 2009 · Synced Oct 28, 2026, 3:53 PM EDT
Completed Not applicable Interventional

A Randomized Control Trial for Preventative Scar Management

NCT01602458
View directory record Official record
Conditions
Hypertrophic Scarring
Interventions
Silicone Only Therapy (SOT), Silicone Pressure Garment Therapy (SPGT)
Procedure
Lead sponsor
Seton Healthcare Family
Other
Eligibility
1 Year to 18 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced Oct 28, 2026, 3:53 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of EXC 001 in Subjects Who Have Participated in Prior Studies of EXC 001

NCT01494922
View directory record Official record
Conditions
Reduction in Severity of Skin Scarring
Interventions
EXC 001 (currently called PF-06473871)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Lake Worth, Florida • Chicago, Illinois • Eugene, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 28, 2026, 3:53 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Seprafilm Slurry in the Prevention of Uterine Scarring in Patients Undergoing Hysteroscopic Myomectomy

NCT01632202
View directory record Official record
Conditions
Intrauterine Adhesions
Interventions
Seprafilm, Sterile Saline Solution
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 48 Years · Female only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Oct 28, 2026, 3:53 PM EDT
Completed Not applicable Interventional Results available

A Study of a Novel Silicone Dressing to Minimize Scar Formation

NCT01399099
View directory record Official record
Conditions
Hypertrophic
Interventions
embrace device
Device
Lead sponsor
Neodyne Biosciences, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
13
States / cities
Atherton, California • Bakersfield, California • Danville, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 28, 2026, 3:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety, Pharmacokinetics, and Preliminary Effect on Scar Formation by RXI-109

NCT01640912
View directory record Official record
Conditions
Cicatrix, Scar Prevention
Interventions
RXI-109, Placebo
Drug
Lead sponsor
RXi Pharmaceuticals, Corp.
Industry
Eligibility
21 Years to 50 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Oct 28, 2026, 3:53 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Revised Hypertrophic Scars

NCT02246465
View directory record Official record
Conditions
Hypertrophic Scar
Interventions
RXI-109
Drug
Lead sponsor
RXi Pharmaceuticals, Corp.
Industry
Eligibility
21 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
5
States / cities
Beverly Hills, California • Lake Worth, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 28, 2026, 3:53 PM EDT
Completed Not applicable Interventional

The Role of 2-octyl Cyanoacrylate in Prevention of Recurrent Adhesions After Circumcision

NCT01794221
View directory record Official record
Conditions
Phimosis, Adhesions
Interventions
stitches and skin adhesive, stitches only
Procedure
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
1 Day to 7 Years · Male only
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Oct 28, 2026, 3:53 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars From Prior Breast Surgery

NCT01037413
View directory record Official record
Conditions
Scar Prevention
Interventions
EXC 001, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
5
States / cities
La Jolla, California • Chicago, Illinois • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 28, 2026, 3:53 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery in Healthy Adults

NCT02030275
View directory record Official record
Conditions
Hypertrophic Scar
Interventions
RXI-109, Placebo
Drug
Lead sponsor
RXi Pharmaceuticals, Corp.
Industry
Eligibility
21 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
4
States / cities
Lake Worth, Florida • Chicago, Illinois • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Oct 28, 2026, 3:53 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of AZX100 Drug Product Following Excision of Keloid Scars

NCT00825916
View directory record Official record
Conditions
Scar Prevention, Scar Reduction
Interventions
AZX100 Drug Product, Placebo
Drug
Lead sponsor
Capstone Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Oct 28, 2026, 3:53 PM EDT
Terminated Phase 3 Interventional

Seprafilm® for Prevention of Adhesions at Repeat Cesarean

NCT00697606
View directory record Official record
Conditions
Adhesion Formation After Primary Cesarean Delivery
Interventions
Seprafilm®, Control
Device · Other
Lead sponsor
Abington Memorial Hospital
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Abington, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 30, 2015 · Synced Oct 28, 2026, 3:53 PM EDT